Sage Therapeutics stock drops
SAGE Therapeutics Inc (SAGE) Stock: Greater Than Its Current Valuation?
On Friday, SAGE Therapeutics Inc (SAGE) stock saw a modest uptick, ending the day at $6.59 which represents a slight increase of $0.22 or 3.45% from the prior close of $6.37. The stock opened at $6.33 and touched a low of $6.
Sage Therapeutics said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after ...
Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...
San Diego, California--(Newsfile Corp. - October 10, 2024) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sage Therapeutics, Inc. (NASDAQ: SAGE) securities between ...
Sage Therapeutics (NASDAQ:SAGE – Get Free Report)‘s stock had its “market perform” rating restated by analysts at Raymond James in a note issued to investors on Thursday, MarketBeat.com reports.
Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the ...
SAGE Therapeutics (SAGE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas ...
Sage Therapeutics is a sell due to failure of SAGE-324 in essential tremors and dalzanemdor's poor performance in Parkinson's ...
On Wednesday, SAGE Therapeutics Inc (SAGE) stock saw a modest uptick, ending the day at $6.49 which represents a slight increase of $0.06 or 0.93% from the prior close of $6.43. The stock opened at $6 ...
Wedbush lowered the firm’s price target on Sage Therapeutics to $8 from $9 and keeps a Neutral rating on the shares. The firm ...
Zacks.com on MSN4d
SAGE's Dalzanemdor Fails to Meet Goal in Alzheimer's Disease StudyShares of Sage Therapeutics, Inc. SAGE were down 4.3% on Oct. 8 after the company announced disappointing top-line data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback